1434 - Anti-Müllerian hormone testing

Page last updated: 22 November 2018

Application Detail



Description of Medical Service

Anti-Müllerian hormone test for the assessment of ovarian function, including ovarian reserve and ovarian responsiveness before or after gonadotoxic treatment

Indication for test
  1. Patients who are being assessed for fertility preservation, prior to gonadotoxic treatment
  2. Long-term follow-up of ovarian function, following completion of gonadotoxic treatment, for the intention of determining complications of gonadotoxic treatment and assess the need for fertility preservation following gonadotoxic treatment, or to recommend the start of assisted reproductive treatment.

Description of Medical Condition

  1. Patients diagnosed with malignancy:

    Currently, 5,660 female Australians aged between 0-45 years are diagnosed with cancer each year.

  2. Patients diagnosed with non-malignant conditions receiving gonadotoxic treatment:
Gonadotoxic treatment can be detrimental to the reproductive potential for several non-malignant medical conditions. Examples of these conditions include:
  • gastrointestinal diseases
  • rheumatologic
  • inflammatory bowel diseases (IBDs),
  • rheumatologic disorders
  • non-malignant hematologic conditions
  • autoimmune/vasculitis/glomerular disorders
  • gynaecologic conditions
  • metabolic diseases

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Consultation Protocol (PDF 1637 KB)
Consultation Protocol (Word 1100 KB)

Assessment Report

Assessment Report (PDF 2574 KB)
Assessment Report (Word 1588 KB)

Public Summary Document

Public Summary Document (PDF 822 KB)
Public Summary Document (Word 404 KB)

Meetings for this Application


14 April 2016
11 - 12 August 2016


8-9 February 2018


28-29 March 2018